Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550523 | 0.94 | ALDH1A1 (0.61) | ALDH1A1MAPTGAAL3MBTL1HTT | |
| SCHEMBL10499283 | 0.92 | ALDH1A1 (0.59) | ALDH1A1MAPTGAAL3MBTL1HTT | |
| SCHEMBL141474 | 0.87 | GAA (0.58) | ALDH1A1MAPTGAAL3MBTL1HTT | |
| SCHEMBL11253095 | 0.84 | MAPT (0.46) | ALDH1A1MAPTHTTTHRBPOLB | |
| SCHEMBL11258268 | 0.83 | ALDH1A1 (0.48) | ALDH1A1MAPTGAAHTT | |
| SCHEMBL5504318 | 0.83 | GAA (0.46) | ALDH1A1MAPTGAAHTTTHRB | |
| SCHEMBL7100388 | 0.80 | GAA (0.47) | ALDH1A1MAPTGAAL3MBTL1HTT | |
| SCHEMBL11309666 | 0.80 | ALDH1A1 (0.48) | ALDH1A1MAPTGAAL3MBTL1HTT | |
| SCHEMBL5551251 | 0.80 | MAPT (0.59) | ALDH1A1MAPTGAAL3MBTL1HTT | |
| SCHEMBL11650662 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MAPTGAAL3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119875390-A | 3- [ [4- [ (2-R3) R4 amino-3-R2 ] phenyl ] azo ] -R1-nitrobenzene red dye and preparation method thereof | 浙江大恒新材料有限公司 | 2025-04-25 | — | — | CN | claimed |
| US-20260108521-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2026-04-23 | — | — | US | disclosed |
| EP-4598918-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-08-13 | — | — | EP | disclosed |
| CN-119875390-A | 3- [ [4- [ (2-R3) R4 amino-3-R2 ] phenyl ] azo ] -R1-nitrobenzene red dye and preparation method thereof | 浙江大恒新材料有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2024073871-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-04-11 | — | — | WO | disclosed |
| CN-102361887-A | Polymers functionalized with nitrile compounds containing a protected amino group | BRIDGESTONE CORP | 2012-02-22 | — | — | CN | disclosed |
| EP-1846383-A2 | RIGIDIFIED COMPOUNDS FOR MODULATING HEPARANASE ACTIVITY | Insight Biopharmaceuticals Ltd. (IL) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006072953-A2 | RIGIDIFIED COMPOUNDS FOR MODULATING HEPARANASE ACTIVITY | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2006-07-13 | — | — | WO | disclosed |
| EP-1259475-A4 | TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS | UNIV YALE (US) | 2004-08-18 | — | — | EP | disclosed |
| EP-1259475-A1 | TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS | YALE UNIVERSITY (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6479592-B2 | SUITABLE IN AS A DENTAL MATERIAL AND ESPECIALLY AS A CONSTITUENT OF DENTAL ADHESIVES OWING TO AN ADHESION-BOOSTING EFFECT | IVOCLAR VIVADENT AG (DE) | 2002-11-12 | — | — | US | disclosed |
| WO-2001064620-A1 | TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS | YALE UNIVERSITY (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108521-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | GHSR, GSPT1, GLRA1 | ALDH1A1 3997/4885MAPT 910/4885GAA 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.